Free Trial

NuCana (NCNA) Competitors

NuCana logo
$0.06 +0.01 (+11.42%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$0.06 0.00 (-0.54%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NCNA vs. PTEIQ, ASLN, CWBR, EVFM, PBLA, PTPI, NMTR, TRVN, HEPA, and SRNE

Should you be buying NuCana stock or one of its competitors? The main competitors of NuCana include PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Evofem Biosciences (EVFM), Panbela Therapeutics (PBLA), Petros Pharmaceuticals (PTPI), 9 Meters Biopharma (NMTR), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), and Sorrento Therapeutics (SRNE). These companies are all part of the "pharmaceutical products" industry.

NuCana vs. Its Competitors

PolarityTE (NASDAQ:PTEIQ) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

PolarityTE has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than PolarityTE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PolarityTE$810K0.00-$7.83M-$3.28N/A
NuCanaN/AN/A-$24.28M-$7.02-0.01

PolarityTE's return on equity of -106.08% beat NuCana's return on equity.

Company Net Margins Return on Equity Return on Assets
PolarityTEN/A -106.08% -76.91%
NuCana N/A -319.85%-88.55%

11.8% of PolarityTE shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 5.4% of PolarityTE shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NuCana has a consensus price target of $25.00, suggesting a potential upside of 44,864.03%. Given NuCana's stronger consensus rating and higher probable upside, analysts plainly believe NuCana is more favorable than PolarityTE.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PolarityTE
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NuCana
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, PolarityTE's average media sentiment score of 0.00 equaled NuCana'saverage media sentiment score.

Company Overall Sentiment
PolarityTE Neutral
NuCana Neutral

PolarityTE has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, NuCana has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.

Summary

NuCana beats PolarityTE on 7 of the 12 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NCNA vs. The Competition

MetricNuCanaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$300K$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-0.0120.8027.0020.10
Price / SalesN/A286.98435.75120.29
Price / CashN/A41.1936.8257.86
Price / Book0.047.487.985.56
Net Income-$24.28M-$55.04M$3.16B$248.40M
7 Day PerformanceN/A2.44%2.40%4.67%
1 Month PerformanceN/A1.90%2.19%6.64%
1 Year PerformanceN/A4.35%33.82%21.31%

NuCana Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NCNA
NuCana
2.5042 of 5 stars
$0.06
+11.4%
$25.00
+44,864.0%
-98.1%$300KN/A-0.0130Gap Up
PTEIQ
PolarityTE
N/AN/AN/AN/A$1.24M$810K-0.0560Gap Up
ASLN
ASLAN Pharmaceuticals
N/A$0.60
flat
N/AN/A$1.23M$12M-0.0330
CWBR
CohBar
N/A$0.41
flat
N/AN/A$1.19MN/A0.0010
EVFM
Evofem Biosciences
0.5858 of 5 stars
$0.01
+4.3%
N/A-14.5%$1.16M$11.39M-0.02120Gap Down
PBLA
Panbela Therapeutics
0.093 of 5 stars
$0.23
+10.4%
N/A-57.0%$1.13MN/A0.006
PTPI
Petros Pharmaceuticals
0.6404 of 5 stars
$0.03
-5.4%
N/A-99.7%$1.04M$5.11M-0.0120Gap Down
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/A-0.0220
TRVN
Trevena
1.5868 of 5 stars
$1.05
-5.4%
$5.00
+376.2%
-83.0%$1.01M$443K-0.0240News Coverage
Gap Down
High Trading Volume
HEPA
Hepion Pharmaceuticals
0.5469 of 5 stars
$0.08
+14.0%
N/A-99.9%$874KN/A-0.0220Gap Down
SRNE
Sorrento Therapeutics
0.6903 of 5 stars
$0.00
-36.4%
N/A-87.3%$772K$60.32M0.00800Gap Down

Related Companies and Tools


This page (NASDAQ:NCNA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners